AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Research

FDA Advisory Committees to Examine a Number of HIV Issues in May

FDA

The U.S. Food and Drug Administration (FDA) has three important advisory committee meetings scheduled in May that may impact HIV prevention, detection, and treatment. On May 10, 2012, FDA’s Antiviral Advisory Committee will discuss expanding the indication of Truvada (emtricitabine/tenofovir disoproxil fumarate) tablet, made by Gilead Sciences, Inc., to include use for Pre-Exposure Prophylaxis (PrEP),…

Updated HHS Adult and Adolescent Antiretroviral Treatment Guidelines Now Available

AIDS Info Guidelines

The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents released updated Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents last week. Revisions to the October 14, 2011, version of the guidelines include both new sections and key updates to existing sections, including: New section on HIV and the older patient…

Conversation from CROI: Dr. Jonathan Mermin on PrEP and an AIDS-free Generation

Mermin YouTube still

At the recent 19th Conference on Retroviruses and Opportunistic Infections (CROI), Dr. Ron Valdiserri, Deputy Assistant Secretary of Health for Infectious Diseases, spoke with Dr. Jonathan Mermin, Director of CDC’s Division of HIV/AIDS Prevention. They discussed some of the significant findings from the conference including advances related to pre-exposure prophylaxis (PrEP) and the growing discussions…

New Frontiers in HIV Testing

Ronald Validserri

It is understandable why advances in the development of anti-HIV drugs have so dominated media stories about the AIDS epidemic in recent years. The advent of highly active antiretroviral therapy has had such a tremendous impact on HIV morbidity and mortality that early commentators of the phenomenon often referred to “the Lazarus effect” when describing…

The Impact of Missed Health Care Visits on HIV Outcomes and Mortality

Michael Holberg and Ron Valdiserri

At the 19th Conference on Retroviruses and Opportunistic Infections (CROI) [external disclaimer] this week, Dr. Ron Valdiserri, Deputy Assistant Secretary of Health for Infectious Diseases, spoke with Dr. Michael Horberg, Director of HIV/AIDS for Kaiser Permanente and a member of the Presidential Advisory Council on HIV/AIDS (PACHA). They discussed the paper Dr. Horberg is presenting…

Highlights from CROI 2012

Ronald Validserri

The 19th Conference on Retroviruses and Opportunistic Infections  (CROI) officially opened in Seattle on Monday afternoon, March 5th. Over 4,200 researchers, providers, community leaders, and advocates from 83 countries gathered at the Washington State Convention Center to hear the opening plenary session. The first presentation was from Dr. Dennis Burton, an internationally renowned expert in…

Advances in Science Advance the National HIV/AIDS Strategy

Ronald Valdiserri

The President has committed to supporting a National HIV/AIDS Strategy (NHAS) that is “grounded in the best science.” Scientific research efforts have greatly expanded our understanding of HIV/AIDS and produced a large number of critical tools and interventions to help us diagnose, prevent, and treat HIV. The past year has been particularly productive with important…

NIAID Advances Efforts to Restructure Clinical Trials Networks with Funding Announcements

NIAID wordle

Over the past year and a half, many of you followed the AIDS.gov blog post series Future Directions for NIAID HIV Research by Dr. Carl Dieffenbach, Director of the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID) at NIH. Last week, NIAID advanced those efforts by issuing several requests for applications (RFAs)…